Showing 118 of 118on this page. Filters & sort apply to loaded results; URL updates for sharing.118 of 118 on this page
BIODEXA - Bioglass
BIODEXA - Bio-Pharmachemie
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset ...
Biodexa gets Orphan Drug Designation for eRapa in FAP | DataM ...
Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Rating Lowered by Wall ...
Proud for our great achievement! Stay tuned for more!!! | Biodexa ...
BIODEXA 8MG/2ML SOL INY IV/IM X 2ML – Farmacia Velavida
BDRX Stock Overview: Comprehensive Insights on Biodexa Pharmaceuticals ...
Biodexa appoints Precision For Medicine as CRO for eRapa in FAP ...
Compra acciones de Biodexa Pharmaceuticals plc ADS | Precio de $BDRX ...
Biodexa Pharmaceuticals Stock Surges: What’s Next?
Biodexa Pharmaceuticals’ Stock Skyrockets! What’s Happening?
Biodexa Advances eRapa to Phase 3 for FAP Following FDA Meeting, Shares ...
Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled
Biodexa Pharmaceuticals | Animo
Advancing Medicines for a Brighter Future | Biodexa
Biodexa Pharmaceuticals Plc (NASD:BDRX) Seasonal Chart | Equity Clock
BDRX - Biodexa Pharmaceuticals | Fundamentei
Biodexa (Nasdaq: BDRX) Secures FDA Fast Track for eRapa in FAP, a Rare ...
Biodexa Pharmaceuticals (BDRX) Launches Phase 3 Trial for eRapa — Can ...
Biodexa licenses Phase 1 GIST drug from Otsuka | BDRX Stock News
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa ...
Biodexa Shares Soar 128% on Positive Phase 2 Results in Rare Disease ...
Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents ...
Biodexa Prepares to Launch Phase 3 Trial for Rare Cancer Drug With Full ...
Biodexa Enhances Cancer Treatment with eRapa Enrollment Milestone ...
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) - YouTube
Biodexa Pharmaceuticals will rise 8,000% at the open
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent ...
We at Biodexa are excited to start up this pivotal Phase 3 study. We ...
Biodexa Pharmaceuticals Announces $10M Public Offering | Maxim Group ...
Biodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer ...
BDRX | Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready ...
In the News | Biodexa Pharmaceuticals
Biodexa Partners with Animo for Clinical Trial Recruitment
Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tol
FDA clears eRapa Phase 3 for FAP, funded by CPRIT and BDRX | Biodexa ...
Biodexa Pharmaceuticals Announces ADR Ratio Change Effective July 31, 2025
BIODEXA ® - BIO PHARMACHEMIE
Biodexa Pharmaceuticals activates first European Site for Phase 3 ...
Biodexa sponsors American Brain Tumor Association Conference | Biodexa ...
Biodexa Launches Phase 3 Trial for First-Ever FAP Treatment, Eyes $7B ...
Biodexa Pharmaceuticals (BDRX) Stock Price & Overview
Pipeline | Biodexa Pharmaceuticals
Biodexa (BDRX) Gains Momentum Following Acquisition Updates
Buy Biodexa Pharmaceuticals Plc Stock – BDRX Stock Quote Today ...
Biodexa Pharmaceuticals Reports Interim Results Highlighting Strategic ...
BDRX Stock Price, News & Analysis | Biodexa Pharmaceuticals
Biodexa Pharmaceuticals PLC: Biodexa's MX-110 Continues to Show Promise ...
Biodexa Pharmaceuticals Begins Phase 3 Trial for FAP Treatment ...
Biodexa Pharmaceuticals announces outcome of a Type C meeting with FDA ...
Biodexa Pharmaceuticals (BDRX) Stock News | StockTitan
Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary
Our Mission is to Advance Medicines for Patients | About Biodexa
Biodexa Pharmaceuticals Stocks: Surging Hope or Caution?
Biodexa Pharmaceuticals (BDRX) Stock Analysis: $8.65 Target on Recent ...
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare ...
Biodexa Asset Offers Potential to ‘Radically Improve’ Treatment for ...
Biodexa Charts Ambitious Course with New Asset and Leadership - Stocks ...
Biodexa Stocks Shine: Decoding the Surge - StocksToTrade
Biodexa Pharmaceuticals Stock Soaring: Time to Buy? - StocksToTrade
Biodexa Pharmaceuticals prices $10M best-efforts public offering ...
Biodexa Pharmaceuticals Plc (BDRX): Positive Phase 2 Results Propel ...
Biodexa Pharmaceuticals Reports 12-Month Survival in Glioblastoma ...
Biodexa Initiates Phase 3 Serenta Trial for Familial Adenomatous Polyposis
Biodexa licenses Otsuka’s molecular glue OPB-171775 for GIST | BioWorld
Biodexa Pharmaceuticals fights FAP with new treatments | Biodexa ...
Biodexa Licenses Phase 1-Ready Drug Candidate From Otsuka For Rare ...
Biodexa Pharmaceuticals PLC launches $5.0M direct offering | Biodexa ...
Biodex Dexametasona+Tobramicina Solución Oftálmica X 5Ml Bioglass ...
BDRX Stock Price and Chart — NASDAQ:BDRX — TradingView
Biodex 20 Comprimidos - Azul Pet
BIODEX C/ 20 COMP DEXAMETASONA BIOFARM
Biodexa’s Revolutionary Step in Pharma
Biodexa's eRapa Receives US FDA Fast Track Designation for Familial ...
Biodexa’s 25% Surge: What’s Driving the Market?
Biodexa's FAP Drug Receives FDA Fast Track Status Following Positive ...
First Patient Dosed in Phase 2 Trial of Novel Oral Type 1 Diabetes ...
Biodexa's eRapa Shows 29% Polyp Reduction in FAP Trial, Advances Cancer ...
Biodex Dexametasona Injetável 10ml Biofarm - Aluren Soluções ...
Bula Biodex Comprimidos | PDF
FDA Fast Track Designation Awarded to Biodexa's FAP Treatment After ...
Biodexa's 52% Surge: A Biotech Breakthrough or Volatile Hype?
Biodexa's 40% Surge: A Biotech Breakthrough or Volatile Hype?
Is Biodexa’s Stock Surge Sustainable?
BDRX Stock (Biodexa Pharmaceuticals stock analysis) BDRX STOCK ...
Pharma News | Biodexa, AbbVie, Insmed
Vet Bio Remedies - Veterinary Medicines
Produtos - Biofarm
Biodexa’s Bold Moves Stir Markets!
Maxim Group
Biodexa's 14% Plunge: Technical Breakdown or Sector Rotation?
BDRX Stock Soars: Time to Invest?
%202024%20copy.jpg)
